Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease

Authors Kimmel SR

Published 8 August 2008 Volume 2008:4(4) Pages 739—745


Sanford R Kimmel

University of Toledo College of Medicine, Department of Family Medicine, Toledo, OH, USA

Abstract: Invasive meningococcal disease occurs worldwide causing an estimated 50,000–135,000 deaths each year in addition to significant sequelae. In developed countries the disease is usually sporadic but outbreaks and epidemics, usually due to serogroups B and C, have occurred. In the US, an increasing number of cases are due to serogroup Y. In developing nations, epidemics due to serogroups A and more recently W-135, are common. The tetravalent meningococcal conjugate vaccine to serogroups A, C, Y, and W-135 (MCV4) has been demonstrated to be highly immunogenic and promote immune memory. This article will describe the rationale for the vaccine and its potential role to significantly decrease mortality and morbidity of meningococcal disease in those areas and populations at greatest risk from these serogroups.

Keywords: meningococcal disease, tetravalent meningococcal conjugate vaccine, serogroup

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen

Perri F, Pisconti S, Conson M, Pacelli R, Della Vittoria Scarpati G, Gnoni A, D’Aniello C, Cavaliere C, Licchetta A, Cella L, Giuliano M, Schiavone C, Falivene S, Di Lorenzo G, Buonerba C, Ravo V, Muto P

OncoTargets and Therapy 2015, 8:1345-1349

Published Date: 8 June 2015

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes

von Websky K, Reichetzeder C, Hocher B

Vascular Health and Risk Management 2013, 9:681-694

Published Date: 1 November 2013

Prescribing tests must have curriculum support

Lemon TI, Shah RD

Advances in Medical Education and Practice 2013, 4:91-93

Published Date: 7 May 2013

ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics

Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJR, Somogyi AA

Pharmacogenomics and Personalized Medicine 2012, 5:53-62

Published Date: 18 April 2012

Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid

Keum CG, Noh YW, Baek JS, Lim JH, Hwang CJ, Na YG, Shin SC, Cho CW

International Journal of Nanomedicine 2011, 6:2225-2234

Published Date: 7 October 2011